Compare ARW & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | KYMR |
|---|---|---|
| Founded | 1935 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | N/A | 2020 |
| Metric | ARW | KYMR |
|---|---|---|
| Price | $112.20 | $66.59 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | ★ $102.00 | $69.58 |
| AVG Volume (30 Days) | 491.5K | ★ 698.8K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 9.05 | N/A |
| Revenue | ★ $29,389,382,000.00 | $43,735,000.00 |
| Revenue This Year | $9.50 | $20.81 |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | ★ 3.16 | N/A |
| 52 Week Low | $86.50 | $19.45 |
| 52 Week High | $134.74 | $68.80 |
| Indicator | ARW | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 60.17 |
| Support Level | $101.79 | $63.69 |
| Resistance Level | $108.74 | $68.78 |
| Average True Range (ATR) | 2.34 | 2.85 |
| MACD | 1.11 | -0.20 |
| Stochastic Oscillator | 94.31 | 63.67 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.